Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

770
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
770
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

274
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sudden unilateral audiovestibular loss due to acute labyrinthine haemorrhage can be missed on early MRI brain sequences: case report.

BMJ neurology open·2024
Same author

An Australian State-Based Cohort Study of Autoimmune Encephalitis Cases Detailing Clinical Presentation, Investigation Results, and Response to Therapy.

Frontiers in neurology·2021
Same author

Practical approach to vertigo: a synthesis of the emerging evidence.

Internal medicine journal·2020
Same author

The electrophysiological assessment of visual function in Multiple Sclerosis.

Clinical neurophysiology practice·2019
Same author

Case report of multiple sclerosis diagnosis in an 82-year old male.

Multiple sclerosis and related disorders·2015
Same author

Hirayama disease.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2015

Related Experiment Video

Updated: Sep 28, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K

Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis.

Brett S Travers1, Benjamin K-T Tsang2, Joshua L Barton3

  • 1BEng, MBBS, Neurology Registrar, Sunshine Coast University Hospital, Birtinya, Qld.

Australian Journal of General Practice
|April 1, 2022
PubMed
Summary

Multiple sclerosis (MS) is a central nervous system disorder. This review covers MS diagnosis, disease-modifying therapies (DMTs), and prognosis, aiding general practitioners in patient care.

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Related Experiment Videos

Last Updated: Sep 28, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Area of Science:

  • Neurology
  • Immunology
  • Neuroinflammation

Background:

  • Multiple sclerosis (MS) is a multifocal inflammatory disorder of the central nervous system.
  • Highly effective disease-modifying therapies (DMTs) are available, significantly impacting MS disease activity and long-term disability.

Purpose of the Study:

  • To provide a concise overview of multiple sclerosis (MS) diagnosis.
  • To review current disease-modifying therapies (DMTs) for MS.
  • To discuss the prognosis of MS.

Main Methods:

  • This is a review article.
  • Key aspects of MS diagnosis, DMTs, and prognosis are summarized.
  • Information is tailored for general practitioners.

Main Results:

  • MS diagnosis relies on clinicoradiological evidence of dissemination in time and space.
  • The growing number of DMTs complicates treatment selection for individual patients.
  • Shared care models between neurologists and general practitioners are common in MS management.

Conclusions:

  • Understanding MS diagnosis, DMTs, and prognosis is crucial for effective patient management.
  • General practitioners play a vital role in the shared care of MS patients.
  • This review provides essential information for GPs managing patients with multiple sclerosis.